Zydus Lifesciences Limited share price
NSE: ZYDUSLIFE · ISIN INE010B01027
Key numbers
- Market cap
- ₹ 1,20,089 Cr
- Current price
- ₹ 1,203.90
- 52-week high / low
- ₹ 1,209 / 836
- Stock P/E
- 26.9
- Book value
- ₹ 269.4
- Dividend yield
- 0.08%
- ROCE
- 20.9%
- ROE
- 19.7%
- Debt to equity
- 0.46
- Sales growth (3 yrs)
- 16.5%
- Profit growth (3 yrs)
- 37.0%
- 1-year return
- 16.2%
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 6,290 | 6,467 | 6,780 | 7,434 | 7,802 |
| Operating profit | 2,165 | 2,031 | 1,652 | 1,910 | 1,873 |
| Net profit | 1,171 | 1,467 | 1,042 | 1,273 | 940 |
| EPS (₹) | 11.64 | 14.58 | 10.36 | 12.65 | 9.35 |
Investor presentation summary (2026-08-23)
AI summary of the presentation · tone: Positive · source document
Key numbers
- 55%: Revenue from Branded Business8
- 2. 78 brands with INR 250mn+ revenue as per AWACS MAT June'26 vs 56 in MAT Jun'22
Guidance & outlook
- 1. FY26 average exchange rate of INR 88.33/ US$
- The USFDA granted Priority Review to the NDA3 for Saroglitazar; Expect NDA3 approval by Q4FY27
Growth & demand
- Global Scale and Capabilities Leadership Across Multiple Markets Portfolio and Product Pipeline
- 5. 505(b)(2) pipeline, Biosimilars, Rare disease assets, Rolvedon® Acquisition and preoperatory
Margins & costs
- High MarginsDifferentiated
- Improving Margin Profile (EBITDA)
Capex & expansion
- EU – Portfolio expansion and
- platform for global expansion
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.